The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...
Migraine involves recurrent attacks of moderate to severe head pain, frequently accompanied by sensitivity to light and sound. Credit: Tunatura/Shutterstock.com. Merz Therapeutics has concluded ...
Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...
Vanda has put the late-stage programme for VQW-765 in SAD on ice at it assesses the full dataset. Credit: omahgrafisgk / Shutterstock.com. Vanda Pharmaceuticals has hit pause on a late-stage programme ...
The trial intends to use the clinical findings to guide the future development of PLT012 across liver disease. Credit: Shidlovski/Shutterstock.com. Pilatus Biosciences has dosed the first patient in ...
Efzimfotase alfa offered numerical, but not statistically significant improvements in patient six-minute walk test values in the HICKORY trial in hypophosphatasia. Credit: Lemberg Vector studio / ...
The trial randomised 274 participants to subcutaneous Taltz or the combination, alongside counselling on diet and physical activity. Credit: Pixel-Shot/Shutterstock.com. Eli Lilly and Company has ...
A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with multiple myeloma (MM). In the EXCALIBER-RRMM study ...
The HIV market is set to grow to $27.4bn in 2033. Credit: mayu85 / Shutterstock.com ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral ...
Johnson & Johnson said there is a second pivotal trial of Caplyta in bipolar I. Credit: josefkubes / Shutterstock..com Johnson & Johnson’s (J&J’s) $14.6bn acquisition of Intra-Cellular Therapies is ...
The trial enrolled 248 adults aged 18 to 70 with moderate-to-severe SLE. Credit: Jarun Ontakrai / Shutterstock.com. Beeline Medicines has announced that its global Phase II clinical trial involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results